Elan Pharma International, a subsidiary of Elan Corporation, today announced an agreement to license its proprietary NanoCrystal technology to Roche.
NanoCrystal technology can improve the bio-availability of drugs by transforming them into nanometer-sized particles that can be used to create more effective and convenient dosage forms such as tablets, capsules, liquids, and powders.
The license agreement will provide Roche with access to NanoCrystal technology and the rights to apply the technology to a drug candidate currently in clinical development.
"We are pleased that we are going to continue to work with Roche to apply our NanoCrystal technology to the formulation of this drug candidate," said Mr Paul Breen, executive vice president, Global Services & Operations, Elan.
"For more than 30 years, Elan has been working to meet the challenges of drug delivery and enhance the performance of drugs. By addressing poor water solubility through the use of NanoCrystal technology, Elan Pharma International continues to play a role in furthering the development of drug candidates."
In the agreement, Elan will provide Roche with formulation services and technology in exchange for research revenues, development milestones and royalties on sales of the product incorporating or made using NanoCrystal technology.